WuXi Biologics (Cayman)'s EBIT per Share for the
six
months ended in Dec. 2025 was $0.14.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.25.
During the past 12 months, the average EBIT per Share Growth Rate of WuXi Biologics (Cayman) was 48.60% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 15.10% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 23.40% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 49.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for WuXi Biologics (Cayman)'s EBIT per Share or its related term are showing as below:
WXIBF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 9.4 Med: 57.7 Max: 112
Current: 15.1
During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of WuXi Biologics (Cayman) was 112.00% per year. The lowest was 9.40% per year. And the median was 57.70% per year.
WXIBF's 3-Year EBIT Growth Rate is ranked worse than 50.43% of 1174
companies
in the Biotechnology industry
Industry Median: 15.4
vs WXIBF: 15.10
WuXi Biologics (Cayman) (OTCPK:WXIBF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
WuXi Biologics (Cayman) EBIT per Share Related Terms
WuXi Biologics (Cayman) EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.25
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi Biologics (Cayman) (WXIBF) has a EBIT per Share of $0.25 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on WuXi Biologics (Cayman) and its competitors. According to the industry distribution chart, WuXi Biologics (Cayman) ranks #592 out of 1174 companies in the Biotechnology industry, placing it in the top 50.4%.
Is WuXi Biologics (Cayman)'s EBIT per Share too high?
WuXi Biologics (Cayman)'s current EBIT per Share is $0.25. The Biotechnology industry median EBIT per Share is 15.40. WuXi Biologics (Cayman)'s value of $0.25 is 98.4% below this industry median. Based on the distribution chart, WuXi Biologics (Cayman) ranks #592 out of 1174 companies in the Biotechnology industry, which is below the industry midpoint. Overall, WuXi Biologics (Cayman) has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, WuXi Biologics (Cayman) ranks #592 out of 1174 companies for EBIT per Share. This places WuXi Biologics (Cayman) in the lower half of its industry. The industry median EBIT per Share is 15.40. WuXi Biologics (Cayman)'s value of $0.25 is 98.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,174 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WuXi Biologics (Cayman)'s current EBIT per Share of $0.25 is 98.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on WuXi Biologics (Cayman) and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WuXi Biologics (Cayman)'s current EBIT per Share is $0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) (WXIBF) is currently considered Fairly Valued. The stock's GF Value™ is $5.12, compared to a current price of $4.77 — trading 6.9% below its estimated fair value. The current EBIT per Share is $0.25 and 98.4% below the Biotechnology industry median of 15.40. WuXi Biologics (Cayman)'s overall GF Score™ is 97/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For WuXi Biologics (Cayman) (WXIBF), the current EBIT per Share is $0.25 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WuXi Biologics (Cayman) (WXIBF) Overvalued in 2026?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued.
The current stock price of $4.77 is trading 6.9% below its estimated GF Value™ of $5.12.
GuruFocus considers WuXi Biologics (Cayman) to be Fairly Valued.
Key valuation signals for WXIBF:
EBIT per Share: $0.25
GF Value™: $5.12 vs. price of $4.77 (6.9% below fair value)
Industry Position: 98.4% below the Biotechnology median (#592 of 1174)
No single metric tells the full story. See the WXIBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
97GF Score
Get the complete analysis for WXIBF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WXIBF has been successfully added to your 
